{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:53:30Z","timestamp":1791359610102,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11060-026-05754-6","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:55:23Z","timestamp":1786985723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exclusion of patients with brain metastases from early-phase systemic therapy trials: a cross-sectional analysis of eligibility criteria"],"prefix":"10.1007","volume":"179","author":[{"given":"Cody","family":"Zatzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kojundzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghna","family":"Katyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Tavangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Smoragiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Jane","family":"Lim-Fat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-0308","authenticated-orcid":false,"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"5754_CR1","doi-asserted-by":"publisher","first-page":"vdaf049","DOI":"10.1093\/noajnl\/vdaf049","volume":"7","author":"CK Anders","year":"2025","unstructured":"Anders CK, Van Swearingen AED, Neman J, Joyce JA, Cittelly DM, Valiente M, Zimmer AS, Floyd SR, Dhakal A, Sengupta S, Ahluwalia MS, Nagpal S, Kumthekar PU, Emerson S, Basho R, Beal K, Moss NS, Razis ED, Yang JT, Sammons SL, Sahebjam S, Tawbi HA (2025) Consortium for Intracranial Metastasis Academic Research (CIMARa): global interdisciplinary collaborations to improve outcomes of patients with brain metastases. Neurooncol Adv 7:vdaf049. https:\/\/doi.org\/10.1093\/noajnl\/vdaf049","journal-title":"Neurooncol Adv"},{"key":"5754_CR2","doi-asserted-by":"publisher","first-page":"855182","DOI":"10.3389\/fonc.2022.855182","volume":"12","author":"AY Li","year":"2022","unstructured":"Li AY, Gaebe K, Jerzak KJ, Cheema PK, Sahgal A, Das S (2022) Intracranial metastatic disease: present challenges, future opportunities. Front Oncol 12:855182. https:\/\/doi.org\/10.3389\/fonc.2022.855182","journal-title":"Front Oncol"},{"key":"5754_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","volume":"4(7)","author":"DN Cagney","year":"2018","unstructured":"Cagney DN, Martin AM, Catalano PJ, Brown PD, Alexander BM, Lin NU, Aizer AA (2018) Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non\u2013Small Cell Lung Cancer. JAMA Oncol 4(7):1001\u20131003. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0813","journal-title":"JAMA Oncol"},{"key":"5754_CR4","doi-asserted-by":"publisher","first-page":"101213","DOI":"10.1016\/j.esmoop.2023.101213","volume":"8","author":"K Riecke","year":"2023","unstructured":"Riecke K, M\u00fcller V, Neunh\u00f6ffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, Puppe J, Mundhenke C, L\u00fcbbe K, Hesse T, Thill M, Wuerstlein R, Denkert C, Decker T, Fehm T, Nekljudova V, Rey J, Loibl S, Laakmann E, Witzel I (2023) Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. ESMO Open 8:101213. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101213","journal-title":"ESMO Open"},{"key":"5754_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41416-025-02967-w","volume":"132","author":"A Steindl","year":"2025","unstructured":"Steindl A, Zach C, Berchtold L, Grisold A, Gatterbauer B, Eckert F, Bago-Horvath Z, Hainfellner JA, Exner R, Fitzal F, Pfeiler G, Singer CF, Widhalm G, Bartsch R, Preusser M, Berghoff AS (2025) Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer. Br J Cancer 132:733\u2013743. https:\/\/doi.org\/10.1038\/s41416-025-02967-w","journal-title":"Br J Cancer"},{"key":"5754_CR6","doi-asserted-by":"publisher","first-page":"780379","DOI":"10.3389\/fonc.2021.780379","volume":"11","author":"AC Tan","year":"2022","unstructured":"Tan AC, Boggs DH, Lee EQ, Kim MM, Mehta MP, Khasraw M (2022) Clinical trial eligibility criteria and recently approved cancer therapies for patients with brain metastases. Front Oncol 11:780379. https:\/\/doi.org\/10.3389\/fonc.2021.780379","journal-title":"Front Oncol"},{"key":"5754_CR7","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","volume":"35","author":"NU Lin","year":"2017","unstructured":"Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, White J, Sul J, Perkins L, Beal K, Gaynor R, Kim ES (2017) Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. J Clin Oncol 35:3760\u20133773. https:\/\/doi.org\/10.1200\/JCO.2017.74.0761","journal-title":"J Clin Oncol"},{"key":"5754_CR8","volume-title":"Cancer clinical trial eligibility criteria: brain metastases guidance for industry","author":"U.S. Food and Drug Administration","year":"2020","unstructured":"U.S. Food and Drug Administration (2020) Cancer clinical trial eligibility criteria: brain metastases guidance for industry. U.S. Department of Health and Human Services, Silver Spring"},{"key":"5754_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.23.01777","volume":"42","author":"H Xiao","year":"2024","unstructured":"Xiao H, Vaidya R, Hershman DL, Unger JM (2024) Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials: time series analyses for 2012\u20132022. J Clin Oncol 42:1953\u20131960. https:\/\/doi.org\/10.1200\/JCO.23.01777","journal-title":"J Clin Oncol"},{"key":"5754_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cllc.2025.11.016","volume":"27","author":"I Riano","year":"2026","unstructured":"Riano I, Velez MA, Pomares-Millan H, Blaquier J, Peshin S, Feldman J, Velazquez AI (2026) Expanding lung cancer clinical trial criteria: a systematic review on inclusion of patients with brain metastases and leptomeningeal disease. Clin Lung Cancer 27:92\u201398. https:\/\/doi.org\/10.1016\/j.cllc.2025.11.016","journal-title":"Clin Lung Cancer"},{"key":"5754_CR11","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3390\/curroncol31070275","volume":"31","author":"A Mittal","year":"2024","unstructured":"Mittal A, Moore S, Navani V, Jiang DM, Stewart DJ, Liu G, Wheatley-Price P (2024) What is ailing oncology clinical trials? Can we fix them? Curr Oncol 31:3738\u20133751. https:\/\/doi.org\/10.3390\/curroncol31070275","journal-title":"Curr Oncol"},{"key":"5754_CR12","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaoncol.2021.1359","volume":"7(7)","author":"K Corbett","year":"2021","unstructured":"Corbett K, Sharma A, Pond GR, Brastianos PK, Das S, Sahgal A, Jerzak KJ (2021) Central nervous system\u2013specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung cancer, and melanoma. JAMA Oncol 7(7):1062\u20131064. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1359","journal-title":"JAMA Oncol"},{"key":"5754_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/neuonc\/noz246","volume":"22","author":"RR Patel","year":"2020","unstructured":"Patel RR, Verma V, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Mainwaring W, Augustyn A, Fuller CD, Sulman EP, Yeboa DN, Chung CC, McAleer MF, Li J, Yoshor D, de Groot JF, Mandel JJ, Ludmir EB (2020) Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol 22:577\u2013579. https:\/\/doi.org\/10.1093\/neuonc\/noz246","journal-title":"Neuro Oncol"},{"key":"5754_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD (2019) Brain metastases. Nat Rev Dis Primers 5:5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y","journal-title":"Nat Rev Dis Primers"},{"key":"5754_CR15","doi-asserted-by":"publisher","first-page":"vdaa178","DOI":"10.1093\/noajnl\/vdaa178","volume":"3","author":"S Habbous","year":"2020","unstructured":"Habbous S, Forster K, Darling G, Jerzak K, Holloway CMB, Sahgal A, Das S (2020) Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study. Neurooncol Adv 3:vdaa178. https:\/\/doi.org\/10.1093\/noajnl\/vdaa178","journal-title":"Neurooncol Adv"},{"key":"5754_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","volume":"96","author":"TC Ryken","year":"2010","unstructured":"Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:103\u2013114. https:\/\/doi.org\/10.1007\/s11060-009-0057-4","journal-title":"J Neurooncol"},{"key":"5754_CR17","doi-asserted-by":"publisher","first-page":"114202","DOI":"10.1016\/j.ejca.2024.114202","volume":"208","author":"E Le Rhun","year":"2024","unstructured":"Le Rhun E, Weller M, Anders C, Larkin J, Li J, Moss NS, Tawbi H, Dummer R (2024) Symptomatic melanoma brain metastases: a call for clear definitions and adoption of standardized tools. Eur J Cancer 208:114202. https:\/\/doi.org\/10.1016\/j.ejca.2024.114202","journal-title":"Eur J Cancer"},{"key":"5754_CR18","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22:1692\u20131704. https:\/\/doi.org\/10.1016\/S1470-2045(21)00545-3","journal-title":"Lancet Oncol"},{"key":"5754_CR19","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S1470-2045(23)00334-0","volume":"24","author":"R Dummer","year":"2023","unstructured":"Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H (2023) Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 24:e461\u2013e471. https:\/\/doi.org\/10.1016\/S1470-2045(23)00334-0","journal-title":"Lancet Oncol"},{"key":"5754_CR20","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-10-3095","volume":"17","author":"AM Tsimberidou","year":"2011","unstructured":"Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R (2011) Phase I clinical trial outcomes in 93 patients with brain metastases: the MD Anderson Cancer Center experience. Clin Cancer Res 17:4110\u20134118. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3095","journal-title":"Clin Cancer Res"},{"key":"5754_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, Dhaliwal AJ, Sahgal A, Das S, Chan KK, Jerzak KJ (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23:894\u2013904. https:\/\/doi.org\/10.1093\/neuonc\/noaa285","journal-title":"Neuro Oncol"},{"key":"5754_CR22","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 19:1511\u20131521. https:\/\/doi.org\/10.1093\/neuonc\/nox077","journal-title":"Neuro Oncol"},{"key":"5754_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, M\u00fcller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382:597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"},{"key":"5754_CR24","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Tan S, Bourla AB, Perretti T, Munoz M, Rodrigues TC, Hurvitz SA, Curigliano G (2024) Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med 30:3717\u20133727. https:\/\/doi.org\/10.1038\/s41591-024-03261-7","journal-title":"Nat Med"},{"key":"5754_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41523-025-00856-2","volume":"12","author":"KJ Jerzak","year":"2025","unstructured":"Jerzak KJ, Razis ED, Agostinetto E, Brastianos PK, Gatti-Mays ME, Ahluwalia MS, Anders C, Bartsch R, Cardoso F, de Vries EGE, El-Abed S, Linderholm B, O\u2019Sullivan CC, Sahgal A, Sammons S, Spears PA, Schumacher-Wulf E, Palmieri C, Lin NU (2025) Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases. NPJ Breast Cancer 12:6. https:\/\/doi.org\/10.1038\/s41523-025-00856-2","journal-title":"NPJ Breast Cancer"},{"key":"5754_CR26","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","volume":"34","author":"SM Gadgeel","year":"2016","unstructured":"Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI (2016) Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol 34:4079\u20134085. https:\/\/doi.org\/10.1200\/JCO.2016.68.4639","journal-title":"J Clin Oncol"},{"key":"5754_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, P\u00e9rol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829\u2013838. https:\/\/doi.org\/10.1056\/NEJMoa1704795","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05754-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:34:38Z","timestamp":1791358478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05754-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5754"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05754-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10049038\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involved analysis of publicly available clinical trial protocols registered on ClinicalTrials.gov and did not involve human participants, human tissue, or identifiable patient data. As such, institutional review board approval and informed consent were not required, and no ethics committee review was sought. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. J. J. has acted as a consultant and\/or adviser of Amgen, AstraZeneca, Apo Biologix, BioCon, Daiichi Sankyo, Eli Lilly, Esai, Genomic Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics, Novartis, Organon, Pfizer and Roche; and has received research support from AstraZeneca, BioCon, Eli Lilly, and Pfizer. A.S. has acted as a consultant and\/or adviser of AstraZeneca, BrainLab, CarboFIX, Cerapedics, Elekta AB, Seagen Inc, Servier and Varian; and has received research grants from BrainLab and Elekta AB and travel support from Elekta AB, BrainLab and Seagen. C. Z., I. F., N. D. S., I. K., E. C., E. Z., M. K., F. T., M. S., M. J. L. F. have no conflicts to report.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"43"}}